PIIR Study: Comparison of Genetic Tests for Age-Related Macular Degeneration
NCT ID: NCT02779686
Last Updated: 2016-10-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
32 participants
OBSERVATIONAL
2012-01-31
2012-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Genetic Study of Age-Related Macular Degeneration
NCT00357578
Genetics Study of Wet Age-Related Macular Degeneration (AMD) Non-Responders to Vascular Endothelial Growth Factor (VEGF) Therapy
NCT01310686
Evaluation of the Association Between Genetic Load and Response to Anti-VEGF Therapy in AMD Patients
NCT01644513
Genetic Biomarkers for the Response to Anti-VEGF (Vascular Endothelial Growth Factor).Treatment in Wet Age-related Macular Degeneration (Wet ARMD)
NCT02762188
Genetics in Non-response to Anti-VEGF Treatment in Exudative AMD
NCT01213667
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ARMD Free
Patient free of ARMD on clinical examination
No interventions assigned to this group
ARMD Positive
Patients with evidence of ARMD on clinical examination
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age \>/= 60 years
* Patient's written informed consent
* Ability to comply with the protocol procedures
Exclusion Criteria
* Age \< 60 years
* Macular or retinal pathology other than ARMD
* Known hypersensitivity to any drug included in the treatment protocol
* Any other severe clinical condition that in the judgment of the local investigator would place the patient at undue risk or interfere with the study completion
* Prisoners
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Missouri-Columbia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nancy Holekamp, MD
Role: PRINCIPAL_INVESTIGATOR
Pepose Vision Institute
Mathew MacCumber, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Rush University Medical Center
Arghavan Almony, MD
Role: PRINCIPAL_INVESTIGATOR
University of Missouri-Columbia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rush University Medical Center
Chicago, Illinois, United States
Pepose Vision Institute
Chesterfield, Missouri, United States
University of Missouri-Columbia
Columbia, Missouri, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Seddon JM, Reynolds R, Maller J, Fagerness JA, Daly MJ, Rosner B. Prediction model for prevalence and incidence of advanced age-related macular degeneration based on genetic, demographic, and environmental variables. Invest Ophthalmol Vis Sci. 2009 May;50(5):2044-53. doi: 10.1167/iovs.08-3064. Epub 2008 Dec 30.
Hageman GS, Gehrs K, Lejnine S, Bansal AT, Deangelis MM, Guymer RH, Baird PN, Allikmets R, Deciu C, Oeth P, Perlee LT. Clinical validation of a genetic model to estimate the risk of developing choroidal neovascular age-related macular degeneration. Hum Genomics. 2011 Jul;5(5):420-40. doi: 10.1186/1479-7364-5-5-420.
Zanke B, Hawken S, Carter R, Chow D. A genetic approach to stratification of risk for age-related macular degeneration. Can J Ophthalmol. 2010 Feb;45(1):22-7. doi: 10.3129/i09-209.
Related Links
Access external resources that provide additional context or updates about the study.
RetnaGene product/test information
Macula Risk product/test information
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1200081
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.